Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Der nächste Perpetua? Warum NevGolds neueste Bohrergebnisse den Vergleich mit dem Milliardenwert PPTA nähren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PKX1 | ISIN: SE0012570448 | Ticker-Symbol: 5J6
Stuttgart
06.06.25 | 08:14
1,270 Euro
-1,55 % -0,020
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
OSSDSIGN AB Chart 1 Jahr
5-Tage-Chart
OSSDSIGN AB 5-Tage-Chart
RealtimeGeldBriefZeit
1,2541,29812:07
1,2601,28206.06.

Aktuelle News zur OSSDSIGN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiKarolinska Development AB (publ): Karolinska Development's portfolio company OssDsign raises approximately SEK 158 million, announces an updated strategy and revises financial targets20
DiOSSDSIGN AB: OssDsign has carried out a directed share issue of approximately SEK 158 million11
DiOSSDSIGN AB: OssDsign explores the conditions for increasing the scope of the directed share issue to approximately 11.5 million shares3
DiOSSDSIGN AB: OssDsign explores the conditions to carry out a directed share issue and announces an updated strategy and revised financial targets3
OSSDSIGN Aktie jetzt für 0€ handeln
14.05.OSSDSIGN AB: OssDsign included in MSCI index12
14.05.OSSDSIGN AB: OssDsign publishes Annual Report 20246
13.05.Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign has treated 10,000 patients with OssDsign Catalyst in the US2
12.05.NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN OSSDSIGN AB2
12.05.OssDsign AB: 10,000 patients treated with OssDsign Catalyst in the U.S.142Uppsala, May 12, 2025. Today, OssDsign AB (publ.) announces that it has reached its milestone of 10,000 patients treated with the innovative nanosynthetic bone graft, OssDsign Catalyst, confirming its...
► Artikel lesen
06.05.OssDsign AB: OssDsign AB (publ) publishes Q1 2025 interim report76Strong growth and best operating result everOssDsign AB (publ) announces that the interim report for Q1 2025 is now available as a PDF on the company's website www.ossdsign.com/reports. A PDF version...
► Artikel lesen
30.04.Karolinska Development AB (publ): Karolinska Development portfolio company OssDsign will change CEO during second half of 20253
30.04.OssDsign AB: OssDsign announces CEO transition planned for the second half of 202579Uppsala, April 30, 2025. OssDsign® AB (publ.) today announces that Morten Henneveld will step down as CEO at the end of the year to support the establishment of leadership with an even stronger presence...
► Artikel lesen
11.04.OSSDSIGN AB: Groundbreaking Study Highlights Enhanced Bone Formation with Novel Silicate-Containing Synthetic Bone Grafts11
09.04.OSSDSIGN AB: 24-month follow up data from the clinical study of OssDsign Catalyst® show 100% spinal fusion3
25.02.OSSDSIGN AB: OssDsign reaches its target of 300 patients enrolled in the prospective spinal fusion registry PROPEL7
04.02.OssDsign AB: OssDsign AB (publ) publishes year-end report 2024118Strategic transformation completed with proven scalability OssDsign AB (publ) announces that the year-end report for 2024 is now available as a PDF on the company's website www.ossdsign.com/reports....
► Artikel lesen
18.12.24Extraordinary General Meeting held in OssDsign AB3
10.12.24Karolinska Development AB (publ): Karolinska Development divests 4,6 million shares in portfolio company OssDsign4
12.11.24OssDsign AB: OssDsign AB (publ) publishes Q3 2024 Interim Report and raises guidance on gross margin140OssDsign AB (publ) announces that the interim report for Q3 2024 is now available as a PDF on the company's website www.ossdsign.com/reports. A PDF version is also attached to this press release. The...
► Artikel lesen
20.08.24OssDsign AB: OssDsign AB (publ) publishes Q2 2024 Interim Report127Reaching milestone in orthobiologics sales OssDsign AB (publ) announces that the interim report for Q2 2024 is now available as a PDF on the company's website www.ossdsign.com/reports. A PDF version...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2